Potential Antiviral Herbal Therapeutics for Viral Infections

Literature Review of Novel Antiviral Agents

Medicinal plant viewpoint Methods are required to connect laboratory-based studies on antiviral efficacy/ potency. Despite this, there is reason for optimism regarding the long-term effectiveness of phyto-antiviral agents given the recent relative success obtained using medicinal plant/ herb extracts of various species that can act therapeutically in various viral infections. This review highlights the vast array of potentially beneficial medicinal plants and herbs that are awaiting evaluation and use for therapeutic applications against genetically and functionally varied virus families like Retroviridae, Hepadnaviridae, and Herpesviridae [4].

Antiviral Agents

Antiviral drugs are a class of medication used specifically for treating viral infections rather than bacterial ones [5]. Most antivirals are used for specific viral infections, while a broad- spectrum antiviral is effective against a wide range of viruses [6]. Unlike most antibiotics, antiviral drugs do not destroy their target pathogen; instead they inhibit their development [7]. Antiviral drugs are one class of antimicrobials, a larger group which also includes antibiotic (also termed antibacterial), antifungal and antiparasitic drugs [8] or antiviral drugs based on monoclonal antibodies [9].

The majority of antivirals are thought to be generally safe for the host, making them useful for treating infections. It is important to separate them from viricides, which aren’t medications but instead deactivate or kill virus particles either inside the body or outside it. Some plants, including Australian tea trees and eucalyptus, naturally produce viricides [10].

Virus Life Cycle

Viruses are made up of a genome and occasionally a small number of enzymes that are kept in a protein capsule called a capsid and occasionally wrapped with a lipid coating known as a “envelope.” Since viruses are unable to reproduce on their own, they spread by controlling a host cell to make copies of themselves, giving rise to the following generation [11]. Researchers trying to create antivirals using such “rational drug design” techniques have attempted to combat viruses at every stage of their life cycles. It has been discovered that some types of mushrooms contain several antiviral compounds that work together in a similar manner [12].

Compounds broad-spectrum antiviral properties when isolated from fruiting bodies and filtrates of different mushrooms, but it will be a considerable time before these substances can be produced and made readily available as frontline antivirals [13].

• The specifics of viral life cycles vary based on the type of virus, but they all follow the same fundamental pattern:
• Attachment to a host cell.
• Release of viral genes and possibly enzymes into the host cell.
• Replication of viral components using host-cell machinery.
• Assembly of viral components into complete viral particles.
• Release of viral particles to infect new host cells.

Anti-Viral Targeting

The main goal of current antiviral medication development is to find viral proteins or segments of viral proteins that can be inhibited. To lessen the possibility of adverse effects, these “targets” should typically be as unlike to any proteins or portions of proteins found in humans as feasible. In order for a single treatment to be effective across a wide range of virus strains, or even across distinct species of virus within the same family, the targets must also be shared. For instance, a researcher may focus on a vital enzyme that is produced by all strains of the virus but not by the patient and investigate what can be done to prevent it from functioning [14].

Candidate medications can be chosen once targets have been identified, either by choosing ones that are already known to have the desired effects or by actually designing the candidate at the molecular level using a computer-aided design programme [15].

By introducing the gene that produces the target protein into bacteria or other types of cells, the target proteins can be produced in the lab for testing with potential treatments. The protein is subsequently produced in large quantities by the cells, which can then be exposed to different treatment options and assessed using “rapid screening” methods [16].

Before Cell Entry

Interfering with a virus’ ability to enter a target cell is one anti-viral tactic. To accomplish this, the virus must first bind to a certain “receptor” molecule on the surface of the host cell, and then it must follow a series of steps that culminate in the virus “uncoating” inside the cell and releasing its contents. Before they may uncoat, viruses with lipid envelopes must fuse their envelope with the target cell or with a vesicle that carries them there [17].

This Stage of Viral Replication can be Inhibited in Two Ways

1. using substances that attach to the cellular receptors and mimic the virus-associated protein (VAP). This could include anti-receptor antibodies, natural receptor ligands, and VAP anti-idiotypic antibodies 2. using substances that bind to the VAP and mimic the biological receptor. This comprises synthetic receptor mimics, exogenous receptors, anti-VAP antibodies, and antibodies against receptor idiotypes [18].

During Viral Synthesis

The processes that create virus components after a virus infects a cell are the focus of a second strategy [18].

Reverse Transcription

Creating analogues of the nucleotides and nucleosides that make up RNA and DNA and disable the enzymes responsible for RNA and DNA synthesis is one technique to achieve this. As opposed to “normal” transcriptase (DNA to RNA), reverse transcriptase inhibition is more frequently linked to this method [19]. Long dsRNA Helix Targeting Long dsRNA helices are produced by the majority of viruses during transcription and replication. Contrarily, during transcription, uninfected mammalian cells often create dsRNA helices with less than 24 base pairs. A class of investigational antiviral medications known as DRACO (double-stranded RNA activated caspase oligomerizer) was first created at the Massachusetts Institute of Technology. DRACO was discovered to be effective against influenza in vivo in weanling mice, in addition to being claimed to have broad-spectrum activity against several infectious viruses in cell culture, including dengue flavivirus, Amapari and Tacaribe arenavirus, Guama bunyavirus, H1N1 influenza, and rhinovirus. According to reports, it selectively causes fast apoptosis in virus-infected mammalian cells while sparing uninfected cells. DRACO causes cell death through one of the final stages of the apoptosis pathway, where complexes with intracellular apoptosis signals are involved. bind many procaspases at once. The procaspases kill the cell by cleaving a variety of cellular proteins, activating other caspases in the cascade, and transactivating other caspases [20].

Immune System Stimulation

Another type of virus-fighting strategies encourages the body’s immune system to combat viruses rather than directly attacking them. Some of these antivirals stimulate the immune system to attack a variety of pathogens rather than concentrating on a single pathogen [21].

Interferons, which prevent the generation of viruses in infected cells, are among the most well-known medications in this group [22]. “Interferon alpha” is a well-known kind of human interferon that is frequently used in the standard care for hepatitis B and C and other interferons are also being investigated as treatments for various diseases [23]. A more specific approach is to synthesize antibodies, protein molecules that can bind to a pathogen and mark it for attack by other elements of the immune system. Once researchers identify a particular target on the pathogen, they can synthesize quantities of identical “monoclonal” antibodies to link up that target. A monoclonal drug is now being sold to help fight respiratory syncytial virus in babies, [24] and antibodies purified from infected individuals are also used as a treatment for hepatitis B [24].

Acquired resistance

Antiviral resistance is characterised by a diminished treatment response brought on by variations in viral genotypes. Drugs’ effectiveness against their intended virus is reduced or absent in cases of antiviral resistance Since the problem has evolved to almost all specific and powerful antimicrobials, including antiviral agents, it inevitably remains a significant barrier to antiviral therapy [25].

Herbal Antiviral agents

preliminary screening by the CPE inhibition assay was carried out against BVDV-1, HSV-1, HSV-2, and influenza A to ascertain the antiviral activity of 15 medicinal plants. The samples that decreased the viral CPE by 2 logs at the MNCC were deemed to be active; their activity was verified using the MTT technique for influenza or the plaque reduction assay for BVDV-1, HSV-1, and HSV-2. For all of the active plant extracts, the Selective Index (SIextract=CC50 extract/EC50 extract), or the ratio between the cytotoxic cell concentration (CC50) and the effective concentration (EC50), was computed. S.

molle (E and I), Cor. didymus (E), M. ilicifolia (I), Phyllantus spp. (E), Er. japonica (I), N. glauca (E and I), Pa. debilis (E), and L. alba (E) were the only plants in this study that were not effective against the tested viruses. High SI values were displayed by the H. bonariensis (I and E), Ce. pachystachya (E), and Cor. didymus (I), all of which were active against BVDV-1 in the screening. Only the infusion of J. australis (E and I) and Er. japonica (E) was effective against HSV-1 and 2 [26].

List of Herbal Antiviral drugs

• Aegle Marmelos 1. (Rutaceae), Linn. Numerous traditional uses of A. marmelos, such as its antibacterial, antiviral, antidiarrheal, gastroprotective, anti- ulcerative colitis, hepatoprotective, antidiabetic, cardioprotective, and radioprotective properties, have been supported by scientific research. This plant has recently attracted interest as a potential anticancer drug for the treatment of various malignancies. This study therefore concentrates on the scientific data supporting A. marmelos’s significant pharmacological activity, including its antioxidant, antidiabetic, antibacterial, hepatoprotective, cardioprotective, and anticancer effects [27].

• The star anise plant, Illicium verum It is also the source of the shikimic acid precursor molecule, which is used in the production of the antiviral drug oseltamivir (Tamiflu®), a treatment for influenza A and influenza B. Moreover, the same plant has yielded a number of additional molecules, some of which have been reported to have biological advantages, such as antiviral effects. Aside from its antiviral potential, star anise also has anti-inflammatory, anti-nociceptive, anti- microbial, anthelmintic, secretolytic, anti-inflammatory, gastroprotective, sedative, expectorant, spasmolytic, and estrogenic properties [28].

• Ayurveda uses a comprehensive methodology to create its descriptions of illness rather than just concentrating on microbiological aetiology [29].

• For the prevention of COVID-19, Ayurveda theory offers straightforward natural methods (daily regimens), herbal combinations, herbsmineral formulations, and activities like yoga. The rejuvenating therapy known as Swasthya Urjaskara Chikitsa includes rasayana therapy. Rasayana is proven to be a very useful instrument in the prevention of any disease since it acts at the level of the Dhatus (tissues) in a Swastha person and administration of Rasayana Aushadi [30].

Click to enlarge

HIV/AIDS and Ayurveda

In Ayurveda, the tridosha Siddhanta, where tridosha affects the Dushya, i.e. dhatus & malas, generating a particular quite pathologies, all the diseases mentioned in Ayurveda are frequently well understood. The discomfort, another ageing sign, a change in complexion, and other damaged organs are frequently used as the names for these illnesses. It is inevitable due to changes in environment and lifestyle; more recent conditions are gaining ground. As a result, they must be treated in accordance with the tridosha principle outlined in classical Ayurvedic texts.